Mounjaro Alternatives: Treatment Options to Discuss
Mounjaro alternatives in the UK include other licensed weight-management medicines, such as Wegovy (semaglutide injection), the Wegovy pill, Foundayo (an oral tablet authorised in 2026), Saxenda (daily liraglutide injection), orlistat and Mysimba (naltrexone and bupropion), as well as NHS weight-management services, structured lifestyle programmes and weight-loss surgery. These work in different ways and suit different people. In the head-to-head SURMOUNT-5 trial, tirzepatide produced more weight loss on average than semaglutide, but average results do not decide what is right for an individual. Products sold as patches, supplements or unlicensed peptides are not alternatives. A prescriber can help you choose based on your health, other medicines, preferences and goals.
The most useful starting point is the reason behind the question, because it changes the answer. A prescriber will want to understand this too.
| If the reason is | What may be worth discussing | Notes |
|---|---|---|
| Cost | A different dose, a different medicine, NHS routes, or a lower-cost licensed option | Price varies by provider and dose, and it changes over time |
| Side effects | Slower dose increases, staying longer on a dose, a different medicine or a different format | Many digestive effects settle; see your prescriber before stopping |
| Prefer tablets to injections | Oral options such as the Wegovy pill or Foundayo | Different routines, such as fasting rules for some tablets |
| Not losing weight | A review of dose, diet and activity, or a different approach | Plateaus are common; see our plateau guide |
| Supply problems | Another licensed medicine, or a different strength | Never use unregulated sources |
| Medical reasons it may not be suitable | Non-GLP-1 options, specialist services or surgery assessment | Your history decides what is safe |
| Wanting to stop | A maintenance plan, gradual dose reduction and support | See our guide to stopping treatment |
Mounjaro contains tirzepatide, which acts on two gut hormone receptors, GIP and GLP-1. The nearest alternatives work on the GLP-1 pathway.
Wegovy (semaglutide injection)
Wegovy is a once-weekly injection licensed for weight management. It contains semaglutide, which acts on GLP-1. It has the same style of dose escalation and similar side effects to Mounjaro, particularly nausea, vomiting, diarrhoea and constipation. In the 72-week SURMOUNT-5 trial in adults with obesity and no diabetes, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide at higher weight-management doses. Many people still do well on Wegovy, and some tolerate it better. Our Mounjaro vs Wegovy guide goes into the detail.
Wegovy pill (oral semaglutide)
This is a daily tablet containing semaglutide. It suits people who do not want weekly injections, but it comes with specific routine rules, such as taking it on an empty stomach with a small amount of water and waiting before eating or drinking. Weight loss on tablets and injections is not identical, so it is worth discussing expectations.
Foundayo (orforglipron)
Foundayo is a once-daily oral GLP-1 medicine authorised in the UK in 2026. It is a small-molecule tablet rather than a peptide, with its own dosing and eating guidance. Because it is newer, long-term real-world experience is more limited.
Saxenda (liraglutide)
Saxenda is an older GLP-1 medicine given as a daily injection. It is licensed for weight management, and NHS use is generally through specialist weight-management services. Weight loss on average is smaller than with newer medicines, and the daily injection and the dose escalation over several weeks are factors to weigh. Happy Pharmacy does not currently supply Saxenda, so this is general information.
Whichever you consider, remember that none of these medicines is used alongside Mounjaro. They should not be combined, and any switch should be planned with a prescriber, who will decide the starting dose.
Average weight loss in the 72-week SURMOUNT-5 trial in 751 adults with obesity and no diabetes, at the highest tolerated dose. Bars drawn to scale. A head-to-head trial result is an average, and individual results vary.
Orlistat
Orlistat works in the gut rather than the brain. It blocks the absorption of about a third of the fat in a meal, and the unabsorbed fat passes out in the stool. It is taken with meals that contain fat. A lower-strength version can be bought without prescription by adults who meet the criteria, and a stronger version is available on prescription. The main drawbacks are digestive: oily stools, urgency, wind and leakage, particularly after high-fat meals. Weight loss is generally more modest than with GLP-1 medicines. Happy Pharmacy does not currently supply orlistat, so this is general information.
Mysimba (naltrexone and bupropion)
Mysimba is a prolonged-release tablet combining naltrexone and bupropion, which act on appetite and reward pathways in the brain. The UK product information describes it as an adjunct to a reduced-calorie diet and more physical activity in adults with a BMI of 30 or more, or 27 and above with at least one weight-related condition. Treatment should be stopped after 16 weeks if at least 5% of body weight has not been lost. It is not suitable for everyone: it must not be used with opioid medicines, in uncontrolled high blood pressure, with a history of seizures, in bipolar disorder or eating disorders, among other contraindications. Happy Pharmacy does not currently supply Mysimba, so this is general information, and your GP or another prescriber can advise on availability.
Medicines for conditions that also affect weight
If you have type 2 diabetes, polycystic ovary syndrome, an underactive thyroid, depression or sleep apnoea, treating that condition may also affect your weight, and some medicines you currently take may contribute to weight gain. A medicines review is a useful step before changing anything.
| Option | How it is taken | How it works | Points to weigh |
|---|---|---|---|
| Mounjaro (tirzepatide) | Weekly injection | GIP and GLP-1 receptors | Strong average results; digestive side effects |
| Wegovy (semaglutide) | Weekly injection | GLP-1 receptor | Well-studied; slightly lower average loss in SURMOUNT-5 |
| Wegovy pill | Daily tablet | GLP-1 receptor | No injections; strict daily routine |
| Foundayo (orforglipron) | Daily tablet | Oral GLP-1 receptor agonist | Newer; tablet routine |
| Saxenda (liraglutide) | Daily injection | GLP-1 receptor | Smaller average loss; daily injection |
| Orlistat | Capsule with meals | Blocks fat absorption | Modest results; oily stools |
| Mysimba | Daily tablets | Appetite and reward pathways | Many contraindications; review at 16 weeks |
- NHS weight-management services: depending on where you live, your GP can refer you to local services, which may include group programmes, specialist teams and, in some areas, access to certain medicines.
- NHS Digital Weight Management Programme: a free, online, referral-based programme for adults with obesity and a diagnosis such as diabetes or high blood pressure. Your GP can tell you whether you are eligible.
- Commercial programmes: structured diet and activity programmes may suit people who want support without medicine, with evidence varying between programmes.
NHS eligibility for weight-loss medicines is limited, and our guide to NHS eligibility explains the criteria. Waiting times vary.
Bariatric surgery, such as gastric bypass or sleeve gastrectomy, can produce larger and longer-lasting weight loss than any medicine for people with severe obesity, and it can improve or even resolve type 2 diabetes. It involves a major operation, lifelong nutritional follow-up and specific risks, and it is generally offered through specialist NHS services or privately to people who meet criteria. Surgery is a serious decision, and a specialist assessment is the first step.
Option 5: Staying on Mounjaro but changing howSometimes the best alternative is not a different medicine but a different way of using the same one. A prescriber may consider a longer time on a lower dose, a gentler schedule, or a maintenance plan once you reach a goal. Our guides to Mounjaro maintenance, tolerance and microdosing explain these approaches and what the evidence does and does not show.
What is not a real alternative- Weight-loss patches: there is no good evidence that patches deliver an effective dose of anything that causes weight loss.
- GLP-1 supplements and natural boosters: these are not medicines, and they do not replicate the effects of prescribed treatment.
- Unlicensed peptide injections and unregulated products sold online, including copies of branded medicines: they may be fake, contaminated or wrongly dosed. See our guide to spotting fake weight-loss injections.
- Extreme diets, laxatives, diuretics or detox products: these are unsafe and ineffective for lasting weight management.
BUY ONLY FROM REGULATED SOURCES
Prescription-only weight-loss medicines should only be supplied by a registered pharmacy after an assessment by a prescriber. You can check a pharmacy on the General Pharmaceutical Council register. If a product is sold without a consultation, at a price that looks too good to be true, or in unfamiliar packaging, do not use it.
- What am I aiming for, and what does success look like for me?
- What is the main reason I am considering a change?
- Which options are licensed for my BMI and health conditions?
- Do my other medicines, history or plans (such as pregnancy) affect what is suitable?
- How will side effects, cost and routine compare?
- What follow-up and review points will there be?
Not every option listed is supplied by every pharmacy. Happy Pharmacy currently supplies Mounjaro, Foundayo, Wegovy and the Wegovy pill, and the other options here are included as general information. It is worth asking any provider what they can prescribe and what they would refer elsewhere.
Common myths- “The newest medicine is always best.” Newer is not always better for an individual, and long-term experience is limited for newer drugs.
- “Tablets work the same as injections.” Different medicines have different average results and routines.
- “If one medicine did not work, none will.” Individual responses vary, and a different approach may help.
- “Natural alternatives are safer.” Natural does not mean effective or safe, and many such products are unproven.
- “I can switch myself.” Switching needs a prescriber, particularly to decide the starting dose.
The bottom line
There is no single best alternative to Mounjaro, because the right choice depends on why you are asking. Other licensed GLP-1 medicines, such as Wegovy, the Wegovy pill, Foundayo and Saxenda, work on the same hormone pathway with different routines and results. Orlistat and Mysimba work differently and suit different people, NHS services and surgery sit on separate pathways, and staying on Mounjaro with a different plan is sometimes the answer. Patches, supplements and unregulated products are not alternatives. Start with your reason for wanting to change, and let a prescriber match a licensed option to your health and goals.
Weighing up your options?
Our GPhC-registered pharmacy team can talk through what may suit you and what to ask your prescriber.
Start Your Free Online Consultation Use code SWITCH10 if you're switching from another provider Happy Pharmacy is a GPhC-registered pharmacy (No. 9013192). Superintendent Pharmacist: Palvinder Deol. Rated 4.8★ Excellent on TrustpilotMedical disclaimer. This guide is for general information and is not a substitute for personal medical advice. Weight-loss medicines are prescription-only and are not suitable for everyone. Always follow the patient information leaflet and the advice of your prescriber or pharmacist.
- Mounjaro (tirzepatide) KwikPen: UK Summary of Product Characteristics. electronic Medicines Compendium (emc).
- Wegovy (semaglutide) solution for injection in pre-filled pen: UK Summary of Product Characteristics. emc.
- Mysimba 8 mg/90 mg prolonged-release tablets: UK Summary of Product Characteristics, sections 4.1, 4.2, 4.3 and 4.4. emc.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.
- NICE. Liraglutide for managing overweight and obesity (TA664). 2020.
- NICE. Overweight and obesity management (NG246). 2025.
- NHS. NHS Digital Weight Management Programme.
- Foundayo (orforglipron): UK marketing authorisation for weight management and type 2 diabetes, August 2026.